Interview Abou-Alfa cabozantinib onto the platform of systemic therapies for liver cancer. I was also involved in evolving the use of combination checkpoint inhibitor therapies. The achieved advances are collectively great, but we shouldn't forget the patient need for a cure, thus our efforts should focus on better understanding and definition of the appropriate applications of CAR-T therapy for liver cancer.
Can you give an overview of the results of the CELESTIAL trial?
The CELESTIAL trial examined the value of cabozantinib, a TKI with a focus on VEGF receptors 1, 2, and 3, MET, and AXL. The trial results demonstrated that versus a placebo in both second-and third-line therapies an improvement of survival, as reported in the New England Journal of Medicine.
Do you foresee US FDA approval of more TKIs for the treatment of hepatocellular carcinoma in the near future?
The FDA have already approved five TKIs, which are sorafenib and lenvatinib as first line treatments. In the second line there is regorafenib with conditional progression on prior-sorafenib, ramucirumab requiring a high AFP level and cabozantinib which is approved as a second-and third-line therapy. We hope that these treatment options will soon be available worldwide.
Will cabozantinib be demonstrated to be effective in combination therapies?
Scientifically, a combination of cabozantinib and checkpoint inhibitors present an intriguing scientific component. The value of such a treatment would be incredibly important to examine, contributing to several other studies looking at combination therapies. The IMbrave150 study evaluating atezolizumab plus bevacizumab demonstrated positive results and was presented at ESMO Asia Congress 2019 (Singapore, 22-24 November 2019). There is also lenvatinib plus pembrolizumab, and lastly a different approach investigating the addition of two checkpoint inhibitors durvalumab and tremelimumab.
The combinations including checkpoint inhibitor are not necessarily all the same. There are so far three types of combinations with the first two being closely related. The antiangiogenic inhibitors combined with an anti PD-L1, for example atezolizumab plus bevacizumab. Second there are TKIs combined with an anti PD-L1, for example lenvatinib plus pembrolizumab or cabozantinib plus nivolumab. And third there are the combination of different checkpoint inhibitors like durvalumab and tremelimumab. We may end up perceiving these three categories as different therapeutic approaches. We are still waiting on the outcomes of several trials to provide the details of how treatment options will evolve accordingly.
In your opinion, what are the current challenges in developing systemic therapies for the treatment of hepatocellular carcinoma?
The interest in the disease is thankfully evolving. Several current options are only available in North America, Western Europe and Japan. One would like to envision that these choices become readily available for patients worldwide. We should not forget the high incidence of liver cancer in Asia, as well as Africa.
Why do you think sponsor support has increased for these therapies?
The main reason is the high-quality science. The credit is due to all those involved in bringing a better understanding of the disease and therapeutic approaches leading to effective treatments.
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